Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 5Hodgkin Disease 2Small Cell Lung Carcinoma 1Sarcoma 1Parathyroid Neoplasms 1Oligodendroglioma 1Neoplasms 1Melanoma Neoplasms 1Lymphoma 1Lung Neoplasms 1Leiomyosarcoma 1Kidney Neoplasms 1Hematologic Diseases 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Colonic Neoplasms 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Doxorubicin 4Radiotherapy 3belinostat 2Trabectedin 2Gemcitabine 2selinexor 1sargramostim 1peposertib 1pembrolizumab 1olaratumab 1liposomal doxorubicin 1itacitinib 1futibatinib 1cixutumumab 1baricitinib 1avelumab 1Specimen Handling 1Radiation 1PTC596 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ifosfamide 1INCB039110 1Fluorouracil 1Erlotinib Hydrochloride 1Dacarbazine 1Chemotherapy, Adjuvant 1Celecoxib 1Biopsy 1BO-112 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leiomyosarcoma × Dacarbazine × Clear all
NCT03761095 2024-03-15

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

PTC Therapeutics

Phase 1 Completed
41 enrolled
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡